Sarepta licenses therapy to boost gene therapies 06-Jul-2020 By Ben Hargreaves Sarepta signs agreement with Hansa to use its treatment as part of a gene therapy treatment schedule.
Dyno launches with gene therapy partnership alongside Novartis 11-May-2020 By Ben Hargreaves The biotech emerges from stealth mode with two partnerships potentially worth in excess of $2bn.
Further safety issues lead to clinical hold for DMD gene therapy 13-Nov-2019 By Ben Hargreaves Solid Biosciences announces that its gene therapy for DMD has been placed under clinical hold again, after a patient experienced a serious adverse event.
US FDA puts gene-therapy on hold after DNA fragment found in plasmids 27-Jul-2018 By Maggie Lynch Sarepta’s gene therapy clinical trial is put on hold by the US FDA after DNA fragment was found in plasmids during quality assurance testing.
